Variable | Baseline (W1) | W2 | W3 | W4 | 1-M (W8) | 2-M (W12) | 3-M (W16) |
Primary | |||||||
Anxiety (STAI-6 questionnaire) | x | x | x | x | x | x | x |
Anxiety (HADS questionnaire) | x | x | |||||
Anxiety (MDP questionnaire) | x | x | |||||
Secondary | |||||||
6-min walking test | x | x | |||||
COPD assessment test | x | x | x | x | x | ||
Descriptive | |||||||
Charlson comorbidity index | x | x | |||||
FEV1 | x | x | |||||
FVC | x | x | |||||
FEV1/FVC | x | x | |||||
BODE | x | x | |||||
mMRC | x | x | |||||
PaO2 | x | x | |||||
PaCO2 | x | x | |||||
GOLD (1–4/A–D) | x | x | |||||
Oxygenotherapy (LTO versus ambulatory) | x | x | |||||
Anxiety-related psychoactive drug intake (dosage/frequency) (exploratory) | x | x | x | x | x | ||
Morphine (dosage/frequency) | x | x | |||||
Anthropometric | |||||||
Age | x | ||||||
Weight | x | ||||||
Height | x | ||||||
Sex | x | ||||||
Body mass index | x | ||||||
Self-reported | |||||||
Smoking status (exploratory) | x | x | x | x | x | ||
Use of self-hypnosis/relaxation (how many times) | x | x | x | x | x | x | |
Re-hospitalisations (how many times) | x | x | x | ||||
Action plan use (how many times) | x | x | x |
Exploratory variables are signalled with the note “(exploratory)” next to their name. Dotted line represents beginning of post-PRP follow-up. W1,…W4: week 1, … week 4; 1-M(W8): 1 month after PRP completion (Week 8 since PRP onset, Week 4 since PRP completion); 2-M(W12): 2 months after PRP completion (Week 12 since PRP onset, Week 8 since PRP completion); 3-M(W16): 3 months after PRP completion (Week 16 since PRP onset, Week 12 since PRP completion). STAI-6 score: state-trait anxiety inventory – six-item version; HADS: Hospital Anxiety and Depression Scale score; MDP: Multidimensional Dyspnoea Profile; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEV1/FVC: Tiffeneau score; BODE: grading system based on a composite score from body mass index, airway obstruction, dyspnoea and exercise capacity; mMRC: Modified Research Council Questionnaire score; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; GOLD: Global Initiative for Obstructive Lung Disease criteria (1–4/A–D); age: in years; sex: male/female; Oxygenotherapy: Long term (LTO) or ambulatory.